AI assistant
Sending…
Viking Therapeutics, Inc. — Director's Dealing 2021
Jan 6, 2021
31359_dirs_2021-01-06_1851f239-c870-4bf3-8d13-a4fc6c9274da.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Viking Therapeutics, Inc. (VKTX)
CIK: 0001607678
Period of Report: 2021-01-04
Reporting Person: Rowland Charles A Jr (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-04 | Stock Option (Right to Buy) | $5.80 | A | 22000 | Acquired | 2031-01-04 | Common Stock (22000) | Direct |
More from Viking Therapeutics, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 26
Interim / Quarterly Report
2026
Apr 30
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Feb 11
Annual Report
2026
Feb 11
Director's Dealing
2026
Jan 26
Director's Dealing
2026
Jan 26
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6